

1 **SUPPLEMENTARY INFORMATION**

2

3 **Inhibition of respiratory Complex I by copper(II)-bis(thiosemicarbazonato) complexes**

4

5 Karrera Y. Djoko^{1#}, Paul S. Donnelly² and Alastair G. McEwan¹

6

7 ¹School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia,
8 QLD, 4072, Australia

9 ²School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, The
10 University of Melbourne, Parkville, VIC, 3010, Australia

11

12 **#Corresponding author**

13 Karrera Y. Djoko

14 Email: k.djoko@uq.edu.au

15 Mailing address: Bdg 76 Cooper Road, School of Chemistry and Molecular Biosciences, The
16 University of Queensland, St Lucia, QLD 4072, Australia

17 Phone: (+61) 7 3365 4603

18

19 **Keywords:** Cu(gtsm), Complex I, mitochondria

20

1 **SUPPLEMENTARY TABLES**

2

3 **Supplementary Table 1.** Fit parameters for all dose-response curves. Each curve was
 4 generated from at least five data points. Data were fitted to Eq. 1 in Methods. Standard
 5 deviations are shown in brackets.

6


Inhibitor	<i>m</i>		<i>n</i>	
	Values	Average	Values	Average
Cu(at-sm)	> 200		0.8 (0.3)	
Cu(gt-sm)	14.0 (1.0) 13.2 (1.0) 15.4 (0.8) 16.1 (0.6) 19.2 (1.3)	15.6	1.1 (0.1) 1.3 (0.1) 1.2 (0.1) 1.0 (0.1) 0.8 (0.1)	1.1
Cu²⁺_{aq}	18.7 (1.0) 15.4 (1.2) 17.7 (1.5) 12.9 (0.5)	16.2	2.5 (0.3) 2.8 (0.5) 2.8 (0.5) 2.6 (0.2)	2.7
Zn(gt-sm)	41.7 (2.6) 30.8 (2.7) 35.4 (3.7)	36.4	1.0 (0.1) 1.1 (0.1) 1.2 (0.2)	1.1

7

8

1 **SUPPLEMENTARY FIGURES**

2




3

4

5 **Supplementary Figure 1. Aggregation of Cu(atSm).** Solution spectrum of Cu(atSm) (60
6 μM , λ_{max} , 457 nm; ϵ_{457} , $7200 \text{ M}^{-1} \text{ cm}^{-1}$) in NADH: O_2 OR activity assay buffer in the absence
7 (-BSA) and presence (+BSA) of BSA (1 mg mL^{-1}). Spectral data were collected at 0 min
8 (black trace) and 1 – 10 min (red traces). Downward and upward arrows indicate time-
9 dependent decrease and increase in absorbance intensity, respectively.

10



1

2

3 **Supplementary Figure 2. Undetectable reduction of Cu^{II}(gtsm) or dissociation of bio-**


4 **available Cu^I ions.** Solution spectrum of Cu(gtsm) (25 μM , λ_{max} 478 nm, ϵ_{478} 8700 $\text{M}^{-1} \text{cm}^{-1}$)

5 in NADH:O₂ OR activity assay buffer containing bicinchoninic acid (100 μM , λ_{max}

6 $[\text{Cu}^{\text{I}}(\text{Bca})_2]^{3-}$ 562 nm, ϵ_{562} 8000 $\text{M}^{-1} \text{cm}^{-1}$). Spectral data were recorded at 0 min (black trace)

7 and 1 – 10 min (red traces) after addition of SMPs (10 $\mu\text{g mL}^{-1}$).


8



1
2
3 **Supplementary Figure 3. Progress traces for the oxidation of NADH by SMPs.** Each
4 reaction contained NADH (50 μM) and Cu(gtsm) (0, 16, or 50 μM as indicated). SMPs (10
5 μg mL⁻¹) were added to the reaction mixture as indicated. The decrease in solution absorbance
6 at 340 nm was monitored for up to 5 min. The absorbance of Cu(gtsm) in the assay buffer
7 without any NADH or SMP was used to zero the instrument prior to each assay (also see
8 Supplementary Figure 5).

9

1




2

3

4 **Supplementary Figure 4. Kinetic analyses of Complex I inhibition by Cu(gtsm).** Double
5 reciprocal plots of the initial rates of NADH oxidation in the presence of increasing amounts
6 of decylubiquinone as the electron acceptor. Cu(gtsm) was added at a final concentration of 0,
7 5, and 10 μM as indicated. NADH was used at a final concentration of 50 μM. These plots
8 resemble competitive inhibition plots but the intersect occurs in the first quadrant instead of
9 on the y-axis.

10



1

2

3 **Supplementary Figure 5.** Spectral overlap between NADH (black trace), Cu(gtsm) (red

4 trace) and Zn(gtsm) (blue trace) (ca. 50 μ M each).